PRO-spectus

Overview

PRO-spectus is a boutique patient-access services and market-access advisory firm for life sciences manufacturers, combining hub operations (benefits navigation, prior authorization, enrollment management), market-access consulting, and medical/payer policy strategy in a single small-team engagement model. Founded in 2008 by Charmie Chirgwin (RN, Founder & CEO), headquartered in Huntington Beach, California, with operational hubs in Chicago, IL (U.S. payer and channel marketing) and London, UK (EMA and global-to-local launch strategy). Backed by Shore Capital Partners since April 2024.

PRO-spectus is not a high-volume scaled hub. It is a smaller, advisory-led operator that pairs hands-on access casework with payer-policy strategy and acts as an extension of a manufacturer’s market access function. Launch teams that need a 100k+ patient queue with a national footprint should compare against scaled hub vendors instead.

Hub Capability Model

The framework below standardizes how Rx Almanac evaluates hub-services capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, PRO-spectus is evaluated as a boutique advisory-led patient-access operator.

Capability	Buyer should compare	PRO-spectus readout
Therapy initiation and enrollment intake	Digital and human intake, eConsent, missing-information resolution, provider/patient portals, and clean case creation.	Core. Patient support services: insurance benefits navigation, prior authorization processing, supplier coordination, and patient enrollment management.
Benefits verification and coverage triage	Medical/pharmacy benefit verification, eligibility checks, payer-policy lookup, coverage routing, and speed from referral to actionable case.	Core. eServices platform supports electronic benefit verification (eBV); confirm payer-rule depth and turnaround SLAs in RFP.
Prior authorization, appeals, and reimbursement casework	PA initiation, payer-specific forms, clinical documentation, appeals, denial management, and field reimbursement handoffs.	Core. Reimbursement Helpline and Access & Reimbursement Manager (ARM) field services are part of the standard service stack.
Affordability, PAP, and copay operations	Copay, free-drug, bridge, foundation, income verification, PAP renewal, and gross-to-net sensitive affordability logic.	Affordability operations. Copay and affordability program support is in scope; validate program design depth for high-cost specialty brands.
Patient engagement and adherence operations	Omnichannel reminders, clinical education, nursing or training escalation, persistence outreach, and patient-facing support quality.	Engagement model. Adherence tracking is offered alongside benefits navigation; confirm staffing model and clinical-escalation pathways.
Fulfillment, specialty pharmacy, and distribution coordination	Routing to SPs, non-commercial dispensing, DTP shipment, sample/replacement product, 3PL, and cold-chain handoffs.	Coordinator role. PRO-spectus coordinates pharmacy benefit and specialty pharmacy referrals; it does not own dispensing or 3PL.
Program reporting, integrations, and governance	Manufacturer dashboards, KPI reporting, CRM/EHR/API integrations, SLA governance, and operating visibility across vendors.	Reporting layer. AcuityMD integration is positioned as the analytics layer for field-intervention impact on claims; confirm dashboard cadence and data-feed access.

Buyer Fit

• Program fit: Include PRO-spectus when a small or emerging biopharma launch needs an advisory-led access partner that combines hub operations with payer-policy strategy under one accountable team.
• Best-fit buyers: Pharma manufacturers and biotech launch teams in specialty and biologic categories, especially diagnostics or device-adjacent products that need payer-policy advocacy alongside reimbursement casework.
• Less ideal fit: Programs that need a high-volume national hub queue, owned specialty pharmacy or 3PL, or 24/7 contact-center scale.
• Commercial fit: Custom/RFP; expect an advisory + access-services blend with named senior team members staffed as an extension of the manufacturer’s market access group.
• Decision checks: Confirm headcount dedicated to your brand, payer-policy library depth, AcuityMD reporting access, and FebriDx-style ARM field-team capacity if field reimbursement is in scope.

Differentiators

• Advisory + operations combined: Patient support casework, market access consulting, and medical/payer policy advocacy delivered by the same team rather than handed off across three vendors.
• eServices access platform: Digital tooling for benefit verification, PA processing, and program management; positioned as the technology layer behind the hub work.
• Three-pillar service model: Market Access Consulting + Reimbursement Helpline + Access & Reimbursement Manager (ARM) field services, productized through the Lumos / FebriDx partnership.
• AcuityMD analytics integration: Claims-data harmonization across 330M+ patients used to verify whether field interventions translate into utilization.
• Founder-led continuity: Charmie Chirgwin (RN) remains CEO with 30+ years of life sciences experience; Shore Capital backing adds growth capital without changing the operating posture.

RFP Questions

• Which workstreams will PRO-spectus operate directly, and which will be routed to a specialty pharmacy, manufacturer system, or third-party vendor?
• How is the team staffed against your brand — dedicated FTEs, pooled resources, or a hybrid model?
• What payer-policy intelligence does the eServices platform expose, and how often is it refreshed?
• How does AcuityMD integration translate field-rep activity into claims-based utilization reporting?
• What turnaround SLAs apply to benefit verification, prior authorization, appeals, and patient-assistance enrollment?
• How is the ARM field-team model scaled when launch volume ramps?
• Which European launch scenarios does the London hub support, and what is the global-to-local handoff model?

Recent Activity

• 2025-09: Lumos Diagnostics Q3 2025 earnings call referenced PRO-spectus billing, claims, and appeals workflow execution for FebriDx point-of-care test rollout.
• 2025-08: Lumos Diagnostics partnership formally launched, productizing the three-pillar Market Access Consulting + Reimbursement Helpline + ARM field-services model.
• 2025-07: Lumos Diagnostics announced a multi-year market-access partnership through December 2026 for FebriDx.
• 2025: Active presence at Informa Copay & Access Congress; Maximilian Klietmann joined as VP Market Access.
• 2024-04: Shore Capital Partners partnership announced; Ryan Kelley (Founding Partner) named Chairman; strategic hires including Jack Allman (VP Finance) and Amy Madden (SVP People).